07May, 2024 CereVasc Receives FDA IDE Approval for the STRIDE Pivotal Study of the eShunt System for Treatment of Normal Pressure Hydrocephaluscerevasc2024-05-28T21:43:24+00:00May 7th, 2024|Press Release|Read More
07Feb, 2024 CereVasc’s eShunt® System to be Presented at the International Stroke Conference by Dr. Pedro Lylykcerevasc2024-05-10T14:17:27+00:00February 7th, 2024|Press Release|Read More
23Jan, 2024 CereVasc’s eShunt® System Study Data Presented at the ABC WIN Seminarcerevasc2024-10-14T16:28:16+00:00January 23rd, 2024|Press Release|Read More
03Oct, 2023 CereVasc Announces 30th Patient Treated in Pilot Studies of the eShunt® System to treat Communicating HydrocephalusAdmin2023-12-20T22:01:46+00:00October 3rd, 2023|Press Release|Read More
26Sep, 2023 CereVasc eShunt® System Study Data Presented at Congress of Neurological Surgeons MeetingAdmin2023-11-06T22:49:34+00:00September 26th, 2023|Press Release|Read More
18Sep, 2023 CereVasc Receives FDA IDE Approval to Expand its Clinical Study of Patients with Normal Pressure Hydrocephalus Utilizing the Generation 2 eShunt® SystemAdmin2023-11-06T22:46:27+00:00September 18th, 2023|Press Release|Read More
13Sep, 2023 CereVasc eShunt® System Study Data Presented at the European Society of Minimally Invasive Neurological Therapy (ESMINT) Congress in MarseilleAdmin2023-11-06T22:43:59+00:00September 13th, 2023|Press Release|Read More
26Jun, 2023 CereVasc & LianMedical Announce Corporate PartnershipAdmin2023-11-06T22:31:47+00:00June 26th, 2023|Press Release|Read More
14Jun, 2023 CereVasc’s Minimally Invasive Central Nervous System Therapy Delivery System Receives Outstanding Presentation Award at American Society of Gene & Cell Therapy Annual MeetingAdmin2023-11-06T22:29:02+00:00June 14th, 2023|Press Release|Read More
04May, 2023 CereVasc to Present Data on its Minimally Invasive CNS Delivery System at Upcoming American Society of Gene and Cell Therapy Annual MeetingAdmin2023-11-06T22:08:22+00:00May 4th, 2023|Press Release|Read More
